Uncovering the Power of Comprehensive Molecular Profiling: Caris Life Sciences to Showcase Cutting-Edge Research at AACR Annual Meeting

Caris Life Sciences® and its partners in the Caris Precision Oncology Alliance™ (POA) are proud to present four studies across 14 tumor types at the 2023 American Association for Cancer Research (AACR) Annual Meeting from April 14-19, 2023 in Orlando, Florida.

Caris President, David Spetzler, M.S., Ph.D., MBA, will also be leading an AACR Scientist↔Survivor Program® Special Session on Sunday, April 16, to discuss the power of leveraging blood for reliable cancer detection, monitoring and therapy selection. Come visit us at Booth Number 130 to learn more about how Caris is revolutionizing healthcare!

The Caris Precision Oncology Alliance is proud to be represented at the AACR with a number of collaborative abstracts accepted for presentation. These findings, particularly in endometrial and prostate cancer, are indicative of the powerful molecular profiling capabilities of the Alliance and will no doubt lead to a greater understanding of the pathobiology of disease and, potentially, to the development of novel therapeutics.

Chadi Nabhan, M.D., MBA, FACP, Chairman of the Caris Precision Oncology Alliance, highlights the importance of this research and the growing success of the POA sites.

At Caris, our mission is to empower clinicians to make informed decisions about the best treatments for their patients, empower researchers to uncover new targets, and enable the biopharmaceutical industry to develop innovative medicines.

Our AI-driven platform, with over 455,000 lifetime cases, provides invaluable insights into ethnic differences in the molecular and tumor microenvironment, which may ultimately help reduce health disparities and improve outcomes in cancer patients.

Dr. David Spetzler will take the stage at the AACR’s Scientist↔Survivor Program® (SSP) to lead a special interest session, celebrating the 25th anniversary of the program, which bridges the gap between the scientific and cancer survivor and patient advocacy communities.

Moderated by Anna Barker, Ph.D., FAACR, Chief Strategy Officer at the Lawrence J. Ellison Institute and founder and chair of the AACR SSP, the session will focus on the importance and challenges of blood-based cancer detection, monitoring and therapy selection in the fight against this deadly disease.

The Caris Precision Oncology Alliance is an extensive network of 82 cancer centers and academic institutions in the United States and beyond. With access to Caris’ comprehensive database and artificial intelligence platform, these institutions have the tools to set evidence-based standards for cancer profiling and molecular testing in oncology.

This gives them the ability to prioritize therapeutic options and determine which clinical trial opportunities may benefit their patients. Plus, they can use Caris CODEai™ to access cancer treatment information and real-world clinical outcomes evidence for over 350,000 patients, containing over 1 million data points per patient. This alliance is a powerful resource for advancing the field of oncology.

About Caris Life Sciences

Caris Life Sciences® is on a mission to revolutionize healthcare and improve patient outcomes. By using comprehensive molecular profiling, advanced artificial intelligence, and machine learning algorithms, Caris is creating an unprecedented database of clinico-genomic information.

This powerful combination of cutting-edge technology and data is unlocking the secrets of disease and accelerating the discovery of treatments, enabling us to make a real difference in the lives of patients.

Caris is leading the charge in the fight against cancer with its suite of market-leading molecular profiling offerings. From DNA to RNA and proteins, these offerings provide a comprehensive molecular blueprint that allows for more accurate detection, diagnosis, and treatment of patients.

The company’s latest innovation, Caris Assure™, is a revolutionary liquid biopsy assay that combines Whole Exome and Whole Transcriptome Sequencing with serial monitoring, making it the most powerful and comprehensive test of its kind.

Headquartered in Irving, Texas, Caris is a global powerhouse, with offices located in Phoenix, New York, Tokyo, Japan, and Basel, Switzerland. With the mission to offer high-quality services that meet the needs of customers around the world, Caris and its distributors provide services in the U.S., Europe, Asia, and other international markets.

Leave a Comment